Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today announced the launch of its new Biosimilars Advisory Service. The service keeps biopharma clients up-to-date on developments in the rapidly evolving biosimilars space, covering every angle of the biosimilars industry ranging from regulatory, legislative and corporate activities to payer and physician perspectives, and includes:

  --  Quarterly webinars detailing major developments   --  Event-driven analyst calls addressing key market changes   --  Customized event briefings to address the company-specific impact of       market activity   --  Therapeutic area-specific primary research on payer and physician       attitudes toward biosimilar adoption, reimbursement and market drivers   --  Ten-year, annualized therapeutic area-specific market forecasts for       biosimilars, plus brand and biosimilar forecasts for more than 20       brands in the U.S., Japan and EU5 (Germany, France, Italy, Spain, UK)  

The primary research and forecasting modules included with the Biosimilars Advisory Service cover three therapeutic areas:

  --  Oncology: granulocyte colony-stimulating factors (G-CSFs) and       monoclonal antibodies (mAbs)   --  Immunology and Infectious Disease: tumor necrosis factor-alpha (TNF-a)       inhibitors and pegylated interferon-alphas (IFNs)   --  Endocrinology and Nephrology: insulins, human growth hormones and       erythropoiesis-stimulating agents (ESAs)  

There is a webinar scheduled for May 5, 2010 that will kick off the Biosimilar Advisory Service. The webinar entitled Understanding the Biosimilars Landscape: How Will Legislative and Regulatory Changes Affect Corporate Strategies? will discuss how U.S. health care reform and recent changes in pricing and reimbursement strategies in Europe will affect the biosimilars market.

"The biosimilars market is constantly evolving, and Decision Resources' Biosimilars Advisory Service will provide our biopharma clients not only with the knowledge to stay on top of current developments and trends, but also the insight and analysis to maximize opportunities that will ultimately defend and grow their business," said Michael Malecki, Ph.D., product director with Decision Resources. "The comprehensive coverage we provide--from primary research on payer and physician attitudes in the U.S. and EU on biosimilars to market forecasts to the event-driven updates and analysis clients will receive throughout the year--make it a vital service for successful business planning in the biosimilars arena."


Members of the media are welcome to attend our upcoming webinar entitled Understanding the Biosimilars Landscape: How Will Legislative and Regulatory Changes Affect Corporate Strategies? This webinar will be held on Wednesday, May 5 at 10 a.m. U.S. Eastern Time. For more information, please contact Lisa Osgood at 781-296-2606 or by email at

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or

  registered trademarks of their respective holders.      Decision Resources                  Decision Resources, Inc.   Lisa Osgood                         Christopher Comfort   781-296-2606                        781-296-2597         

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Decision Resources: Lisa Osgood, +1-781-296-2606,; Decision Resources, Inc.: Christopher Comfort,

Janssen's Invega Sustenna Will Become Decision Resources' Proprietary Clinical Gold Standard in 2013 for the Treatment of Schizophrenia

View Now